Longevity Manila

For the physician your patient brings this to.

What the compounds are, what is usually monitored, the flags that remove them, and a printable sheet.

A man in a white collared shirt holding a clipboard with a blank page, looking at camera in a white studio

For the people around you

Shape

the protocol it funnels to

Before you start.

  1. Your patient has brought you a protocol sheet built by a rules engine on this site from a fourteen-question quiz. It is not a prescription, and we told them to bring it to you before starting.
  2. This page says what the compounds on that sheet are, what class each belongs to, what is usually monitored for each class, and which flags in the quiz remove compounds entirely.
  3. At the end is a printable sheet your patient fills in from their plan: compounds, schedule, start date, and the two bloodwork columns, with space for your notes.

What your patient has come with.

A printed or saved sheet headed with their first name, listing one to three compounds in the order they start, each with a vial size, a water volume, a dosing ladder with a ceiling, a rhythm through the week, and a week of the ninety days it begins. The sheet carries a baseline before day one and a retest at week twelve, and a line telling them to take it to a doctor who knows them before they begin.

The sheet was produced by a rules engine from fourteen answers: goal, age, sex, current symptoms, sleep, training, body composition intent, prior experience, height and weight, medical flags, budget, location and name. Nobody at this site reviewed the patient. The compounds are research materials, not registered with the Philippine FDA and not approved for human use, and they are supplied by Primara Labs, our partner and supplier.

The seven goals map to these compounds: Shape to Retatrutide and KLOW Blend; Energy to NAD+ and MOTS-c; Recovery to KLOW Blend; Skin to KLOW Blend; Strength to CJC-1295 + Ipamorelin and Tesamorelin; Sleep to DSIP and CJC-1295 + Ipamorelin; Focus to Semax and Selank.

The compounds, one paragraph each.

Literature fetched from PubMed on 2026-09-07. Type labels are ours: RCT, phase 2 or 3, review, preclinical, in vitro, human PK/PD, observational.

RetatrutideIncretin class: GIP, GLP-1 and glucagon receptor agonist
Retatrutide is a once-weekly subcutaneous peptide that acts at the GIP, GLP-1 and glucagon receptors. It is in phase 3 development for obesity and related conditions; the phase 2 obesity and type 2 diabetes trials are cited below, and no primary phase 3 results were indexed on PubMed on the read date. It carries the class warnings of GLP-1 receptor agonists.
Usually monitored: HbA1c; fasting glucose; lipid panel; ALT, AST; creatinine, eGFR; lipase where indicated by symptoms.
TirzepatideIncretin class: dual GIP and GLP-1 receptor agonist
Tirzepatide is a once-weekly subcutaneous dual agonist approved in several jurisdictions for type 2 diabetes and for chronic weight management. The label excerpts below are from the US prescribing information for the obesity indication. It is in the catalogue but the engine leans toward retatrutide for most protocols.
Usually monitored: HbA1c; fasting glucose; lipid panel; ALT, AST; creatinine, eGFR; blood glucose where insulin or a sulfonylurea is co-prescribed.
NAD+Coenzyme, injectable
Nicotinamide adenine dinucleotide is a coenzyme central to cellular energy metabolism. Human trial data exist for oral precursors (nicotinamide riboside and nicotinamide mononucleotide); for injected or infused NAD+ the only controlled human dataset found is a small pharmacokinetic pilot, and efficacy trials are lacking. The page says so.
Usually monitored: fasting glucose; ALT, AST; creatinine, eGFR.
MOTS-cMitochondrial-derived peptide
MOTS-c is a peptide encoded in mitochondrial DNA. The evidence is preclinical: mouse studies of metabolism and physical performance, with endogenous MOTS-c measured in human volunteers after exercise. There is no human treatment trial indexed on PubMed.
Usually monitored: fasting glucose; HbA1c.
KLOW BlendBlend: BPC-157, TB-500, GHK-Cu and KPV
The blend combines two repair peptides, a copper tripeptide and an anti-inflammatory tripeptide in one vial. The literature for each component is cited separately below. BPC-157 and KPV evidence is preclinical; TB-500 is a synthetic fragment of thymosin beta-4 whose human trials used the full-length peptide topically; GHK-Cu human data are cosmetic studies not indexed on PubMed, summarised in the cited reviews.
Usually monitored: CRP; standard panel.
GLOW BlendBlend: GHK-Cu, BPC-157 and TB-500
A sibling blend without the KPV fragment, mixed and taken the same way. The component literature below applies.
Usually monitored: CRP; standard panel.
BPC-157Synthetic gastric pentadecapeptide
BPC-157 is a synthetic fragment derived from a gastric protein. The evidence is animal and in vitro, largely from one originating group; an independent 2025 review states that human data are limited to three small studies.
Usually monitored: standard panel.
TB-500Synthetic fragment of thymosin beta-4
TB-500 is a synthetic fragment of the naturally occurring protein thymosin beta-4. The human trials cited used full-length topical thymosin beta-4 in venous ulcers, not injected TB-500.
Usually monitored: standard panel.
  • The effect of thymosin treatment of venous ulcers. Guarnera G, DeRosa A, Camerini R, et al. Ann N Y Acad Sci 2010;1194:207-12. PMID 20536470. phase 2 RCT, topical. Topical full-length thymosin beta-4 in venous stasis ulcers. TB-500 is a synthetic fragment; these trials did not use injected TB-500.
  • Thymosin β4 Promotes Dermal Healing. Kleinman HK, Sosne G Vitam Horm 2016;102:251-75. PMID 27450738. review. Review of thymosin beta-4 in preclinical and phase 2 dermal wound studies.
GHK-CuCopper tripeptide
GHK-Cu is the tripeptide glycyl-L-histidyl-L-lysine complexed with copper. Human evidence consists of topical cosmetic studies that are not indexed on PubMed and are summarised in the cited reviews; the gene-expression papers are computational and in vitro.
Usually monitored: standard panel.
CJC-1295 + IpamorelinGrowth hormone axis: GHRH analogue with a ghrelin-receptor agonist
CJC-1295 is a long-acting analogue of growth hormone releasing hormone; ipamorelin is a selective growth hormone secretagogue acting at the ghrelin receptor. Both have human pharmacokinetic and pharmacodynamic data in healthy volunteers; long-term controlled efficacy and safety studies are few, as the cited reviews note.
Usually monitored: IGF-1, interpreted against age-adjusted ranges; fasting glucose or HbA1c.
TesamorelinGrowth hormone axis: GHRH analogue
Tesamorelin is a GHRH analogue approved in the United States for excess abdominal fat in HIV-infected patients with lipodystrophy; the pivotal trials are cited below. Its use outside that indication is off-label.
Usually monitored: IGF-1; fasting glucose or HbA1c.
SemaxSynthetic ACTH fragment analogue, intranasal in the literature
Semax is a synthetic heptapeptide analogue of an ACTH fragment developed in Russia. The human studies are Russian-language clinical studies in cerebrovascular disease; the indexed records do not describe randomisation.
Usually monitored: blood pressure where symptomatic.
SelankSynthetic tuftsin analogue, intranasal in the literature
Selank is a synthetic heptapeptide analogue of tuftsin developed in Russia. The human evidence is comparative clinical studies against benzodiazepines in anxiety disorders, without a placebo arm.
DSIPDelta sleep-inducing peptide
DSIP is a nonapeptide first isolated from rabbit brain. The human evidence is two small double-blind studies from the 1980s and 1990s in chronic insomnia, in which objective sleep changes were weak.
PT-141Melanocortin receptor agonist
Bremelanotide is a melanocortin receptor agonist approved in the United States for hypoactive sexual desire disorder in premenopausal women; the two phase 3 trials are cited. The label notes transient blood pressure increases after dosing.
Usually monitored: blood pressure.

What is usually monitored, by class.

For the incretin class, the label of the approved dual agonist is the reference most physicians here reach for. The excerpts below are from the US prescribing information for tirzepatide for the obesity indication, fetched on the date shown, with the brand name replaced by the compound in brackets. Tests named on this site around the class are HbA1c, fasting glucose, a lipid panel, ALT and AST, creatinine and eGFR, and lipase where symptoms warrant. No targets are given here or anywhere on the site.

For the growth hormone axis class, the two reviews cited name IGF-1 interpreted against age-adjusted ranges, and fasting glucose or HbA1c, as the pragmatic minimum, with the caveat that long-term controlled studies are few. The quotations are verbatim.

Tirzepatide injection, US Prescribing Information, DailyMed, revised August 2026. dailymed.nlm.nih.gov, read 2026-09-07.
Boxed warning
“In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether [tirzepatide] causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined. [tirzepatide] is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).”
5.5 Acute Pancreatitis
“Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, or [tirzepatide]. After initiation of [tirzepatide], observe patients carefully for signs and symptoms of acute pancreatitis which may include persistent or severe abdominal pain (sometimes radiating to the back) and which may or may not be accompanied by nausea or vomiting. If pancreatitis is suspected, discontinue [tirzepatide] and initiate appropriate management.”
5.4 Acute Gallbladder Disease
“Treatment with [tirzepatide] and GLP-1 receptor agonists is associated with an increased occurrence of acute gallbladder disease. If cholecystitis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.”
5.7 Hypoglycemia
“There is also increased risk of hypoglycemia in patients treated with tirzepatide in combination with insulin. In patients with diabetes mellitus, monitor blood glucose prior to starting [tirzepatide] and during [tirzepatide] treatment. The risk of hypoglycemia may be lowered by a reduction in the dose of insulin or sulfonylurea (or other concomitantly administered insulin secretagogue).”
8.1 Pregnancy
“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. Advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue [tirzepatide] when a pregnancy is recognized.”
Growth hormone secretagogues, from the two reviews cited above.
  • “Available studies indicate that GHSs are well tolerated, with some concern for increases in blood glucose because of decreases in insulin sensitivity.” PMID 28400207
  • “IGF-1 - while imperfect - typically provides a more interpretable integrated signal of pathway activation over time when measured and interpreted using age-adjusted reference ranges.” PMID 42395176
  • “Fasting glucose or HbA1c worth obtaining regardless of compound class.” PMID 42395176

The flags the engine removes compounds for.

The quiz asks one question with these options. A flag removes compounds from the sheet rather than warning beside them.

  • Pregnant, breastfeeding, or trying to conceiveremoves the incretin class and the growth hormone axis class.
  • Personal or family history of medullary thyroid cancer or MEN2removes the incretin class and the growth hormone axis class.
  • Active cancer, or in treatmentremoves the incretin class and the growth hormone axis class.
  • History of pancreatitisremoves the incretin class.
  • Type 1 or type 2 diabetes on insulin or a sulfonylureacaps the incretin class and refers the patient to a prescriber.
  • Regular prescription medicationremoves nothing; the sheet carries a note asking a prescriber who can see the chart to review the list.

The printable sheet.

Your patient fills this from the Planner and the bloodwork log on their own device; nothing is stored anywhere else. If they are reading this with you, the button prints it now.

Reading the plan on this device.

Longevity Manila · protocol sheet for a physician

Printed 12 September 2026

Patient
Start date

Compounds and schedule

CompoundVial, waterDose on the sheetRhythmFrom week

Bloodwork

TestUnitBaselineDay 90

Physician notes

Built by a rules engine from a fourteen-question quiz at longevitymanila.com. Not a prescription. The compounds are research materials, not registered with the Philippine FDA and not approved for human use. Fulfilment by Primara Labs, our partner and supplier. Nothing on this sheet was reviewed by a physician.

How it fits your protocol.

The sheet your patient holds was built to start with one compound, add a second at week five and, on the largest budgets, a third at week nine, with a baseline before day one and a retest at week twelve. The Planner lays that on a calendar and the bloodwork log keeps the two panels side by side in your laboratory's units, with no ranges or colouring of our own. The bloodwork page names Metro Manila laboratories with published prices.

The compounds are research materials, not registered with the Philippine FDA and not approved for human use, and the site says so on every page. Nothing here is a recommendation to you. It is the reference we would want you to have when a patient arrives with our sheet.

Shape protocols here are built on Retatrutide and KLOW Blend. Yours starts with three minutes.

Get started

Questions

Is this a prescription or a treatment plan?

No. It is the output of a rules engine from a quiz, printed for the patient to bring to you. We are not a clinic and nobody here has reviewed the patient. The decision is yours.

Where do the numbers on the sheet come from?

The engine applies a fixed schedule per compound from a catalogue, with a ladder and a ceiling. They are sequencing figures drawn from the literature and the registered dosing of related products, not individualised advice. This page deliberately does not reproduce them.

What does the engine remove, and why?

Pregnancy or breastfeeding, a personal or family history of medullary thyroid cancer or MEN2, and active cancer remove the incretin class and the growth hormone axis class. A history of pancreatitis removes the incretin class. Diabetes on insulin or a sulfonylurea caps the incretin class and sends the patient to you. Regular prescription medication removes nothing but flags the sheet for your review.

Can I get the patient's data?

Only from the patient. The tools store everything on their device; nothing is sent to us. They can export the Tracker's log as a CSV and the bloodwork log as a file, or print the sheet at the end of this page.

Who wrote this page?

Longevity Manila, a quiz that builds a protocol fulfilled by Primara Labs, our partner and supplier. No physician reviewed it. The citations are primary literature fetched on the date shown beside each.

Related

Longevity Manila builds your protocol from your answers. We are not a clinic. Fulfilment is by Primara Labs, our partner and supplier. Take it to a doctor who knows you before you begin.